文献速递外周动脉疾病

糖尿病与非糖尿病患者股腘动脉药物涂层球囊血管成形术的倾向评分匹配分析

Drug-Coated Balloon Angioplasty for Femoropopliteal Disease in Diabetic Versus Nondiabetic Patients: A Propensity Score-Matched Analysis.
PubMed 文献 · Ann Vasc Surg · 2026-01-03

这项多中心注册研究纳入1,779例完成1年随访的股腘动脉DCB治疗患者,经倾向评分匹配形成597对。结果显示糖尿病与非糖尿病患者的免于临床驱动靶病变血运重建率相当(93.63% vs 93.84%,P=0.912),但糖尿病患者总生存率更低(91.68% vs 95.74%,P=0.009),在CLTI亚组中无截肢生存率也显著更差(81.39% vs 90.19%,P=0.022)。

要点

  • DCB治疗股腘动脉病变时,糖尿病患者与非糖尿病患者的靶病变血运重建率相当。
  • 糖尿病患者总生存率显著低于非糖尿病患者(91.68% vs 95.74%,P=0.009)。
  • CLTI亚组中糖尿病患者无截肢生存率更差,但免于截肢率无显著差异。

核心结论

  • DCB血管成形术在糖尿病与非糖尿病患者中技术成功率和免于靶病变血运重建率相当。
  • 糖尿病患者总生存率显著更低,CLTI亚组中无截肢生存率也显著更差,但免于截肢率相似。

研究设计与样本

  • 多中心注册研究,从2,356例接受DCB治疗的患者中分析1,779例完成1年随访者。
  • 基于糖尿病状态进行倾向评分匹配,形成597对平衡23项人口学和病变特征的匹配对。

主要发现

  • 糖尿病与非糖尿病患者的免于临床驱动靶病变血运重建率分别为93.63%和93.84%(P=0.912)。
  • 两组技术成功率均超过98%。
  • 糖尿病患者总生存率为91.68%,非糖尿病为95.74%(P=0.009)。
  • CLTI亚组(n=431;糖尿病220例,非糖尿病211例)中,无截肢生存率分别为81.39%和90.19%(P=0.022,HR 1.895,95%CI 1.117-3.214)。
  • CLTI亚组免于截肢率分别为99.02%和97.92%(P=0.397,HR 0.488,95%CI 0.098-2.418)。

临床怎么用

  • DCB可作为糖尿病股腘动脉病变患者的有效血运重建选择,靶病变血运重建风险与非糖尿病患者相当。
  • 对合并糖尿病的CLTI患者应关注无截肢生存风险,加强围手术期和术后管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate drug-coated balloon (DCB) effectiveness for femoropopliteal disease in diabetic versus nondiabetic patients, using propensity score matching. METHODS: This multicenter registry analyzed 1,779 patients completing 1-year follow-up from 2,356 enrolled patients undergoing DCB treatment. Propensity matching, based on diabetes status, created 597 matched pairs balanced across 23 demographic and lesion characteristics. Primary endpoints included freedom from clinically driven target lesion revascularization and major adverse events at 12 months. Amputation-free survival and freedom from amputation outcomes were specifically analyzed in the chronic limb-threatening ischemia (CLTI) subgroup. RESULTS: Freedom from clinically driven target lesion revascularization rates were equivalent between diabetic and nondiabetic patients (93.63% vs. 93.84%, P = 0.912), confirming consistent DCB efficacy. Technical success exceeded 98% in both cohorts. Overall survival was 91.68% in diabetic patients versus 95.74% in nondiabetic patients (P = 0.009). In the CLTI subgroup (n = 431; diabetic patients n = 220, nondiabetic patients n = 211), amputation-free survival demonstrated significant risk stratification between diabetic and nondiabetic patients (81.39% vs. 90.19%, P = 0.022, hazard ratio 1.895, 95% confidence interval 1.117-3.214), while freedom from amputation remained excellent without significant difference between diabetic and nondiabetic patients (99.02% vs. 97.92%, P = 0.397, hazard ratio 0.488, 95% confidence interval 0.098-2.418). CONCLUSION: DCB angioplasty demonstrates comparable technical success and freedom from target lesion revascularization in diabetic and nondiabetic patients. However, diabetic patients exhibited significantly lower overall survival and, in the CLTI subgroup, reduced amputation-free survival, despite similar freedom from amputation rates.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Du Y, Zhu Y, Wang X, et al. Drug-Coated Balloon Angioplasty for Femoropopliteal Disease in Diabetic Versus Nondiabetic Patients: A Propensity Score-Matched Analysis. Ann Vasc Surg. 2026. PMID: 41490756. doi:10.1016/j.avsg.2025.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。